Elemental Pet Vets, PLLC, Freeville, New York, USA.
Chi University, Reddick, Florida, USA.
Open Vet J. 2023 Feb;13(2):188-192. doi: 10.5455/OVJ.2023.v13.i2.6. Epub 2023 Feb 11.
Canine cognitive dysfunction (CCD), the dog analog of human Alzheimer's disease (AD), is a progressive neurodegenerative condition that presents many treatment challenges. There are few effective drugs with acceptable side effects for AD/CCD, which has prompted investigation into non-drug options, collectively termed nutraceuticals. Nutraceutical supplements are conceptually divided into conventional (Western) and non-conventional (Eastern) ingredients. Many of these individual supplements have shown in vitro and/or in vivo efficacy in ameliorating neuronal damage in rodent models, and some have demonstrated positive effects on cognition in rodent models and clinical trials in dogs and humans with cognitive impairment.
The purpose of this open-label clinical trial was to investigate the effect of an oral integrative (combination of conventional nutraceuticals and Chinese herbals) supplement (CogniCaps) on cognitive scores when administered to aging dogs with CCD over a 2-month period.
Ten aging (>9-year-old) dogs with moderate (16-33) cognitive scores were recruited and administered oral CogniCaps for two months. No additional drugs or nutraceuticals directed at improving cognitive function were allowed during the study period. Baseline cognitive scores were compared with those procured at 30 and 60 days. Cognitive scores for baseline, 30- and 60-days post-treatment were compared.
Cognitive scores improved at 30 days (38% reduction) and 60 days (41% reduction) post-treatment ( = 0.002). Scores did not differ between 30- and 60-day assessments ( = 0.7).
The results of this small preliminary study suggest that the integrative supplement CogniCaps might improve cognitive scores in dogs with CCD within the first 30 days of administration and that this improvement is sustained at 60-day follow up.
犬认知功能障碍(CCD)是一种类似于人类阿尔茨海默病(AD)的进行性神经退行性疾病,它存在许多治疗挑战。目前针对 AD/CCD,仅有少数副作用可接受的有效药物,这促使人们对非药物选择进行研究,统称为“营养保健品”。营养保健品在概念上分为常规(西方)和非常规(东方)成分。许多这些单独的补充剂已在改善啮齿动物模型中的神经元损伤方面显示出体外和/或体内功效,并且一些补充剂已在认知障碍的啮齿动物模型和临床试验中以及在人类中显示出对认知的积极影响。
本开放性临床试验的目的是研究口服综合(常规营养保健品和中草药的组合)补充剂(CogniCaps)在两个月的时间内对患有 CCD 的老年犬的认知评分的影响。
招募了 10 只年龄较大(>9 岁)的认知评分处于中等水平(16-33)的狗,并给予口服 CogniCaps 两个月。在研究期间,不允许使用其他药物或针对改善认知功能的营养保健品。将基线认知评分与 30 天和 60 天获得的认知评分进行比较。比较治疗前、30 天和 60 天的认知评分。
治疗后 30 天(减少 38%)和 60 天(减少 41%)认知评分改善( = 0.002)。30 天和 60 天评估之间的评分无差异( = 0.7)。
这项小型初步研究的结果表明,综合补充剂 CogniCaps 可能在给药后的前 30 天内改善 CCD 犬的认知评分,并且这种改善在 60 天的随访中得以维持。